"WHITE PAPER" ON NUTRACEUTICALS

3 February 1992

Today various nutrients are being studied for such far-reaching benefits as slowing the aging process and curtailing the adverse health effects of pollution, according to the US-based Foundation for Innovation in Medicine. It says that more and more food and nutritional products are found in government and university-based studies to offer potential or actual benefits in the prevention or treatment of widespread illnesses.

However, there is an absence of any appropriate and efficient review process for the product data claims and other information. This has come about, according to the Foundation, because the government does not directly regulate scientists or the media, or physicians and consumers. It only regulates the industry, which usually has neither sponsored the studies nor, in most cases, made the claims. The Foundation says that, in real-ity, there is no effective regulatory system in the USA regarding medical or health claims for nutraceuticals, despite the fact that these products have entered the mainstream of science, medicine and the consumer marketplace.

For this reason, the Foundation has issued a "White Paper" proposing specific economic and regulatory reforms to establish conditions in the USA for the responsible, research-based development and availability of nutraceuticals, as a growing array of food and nutritional products with health and medical benefits.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight